An intranasal stringent response vaccine targeting dendritic cells as a novel adjunctive therapy against tuberculosis

Styliani Karanika1,2, James T. Gordy3, Pranita Neupane1,2, Theodoros Karantanos4, Jennie Ruelas Castillo1,2, Darla Quijada1,2, Kaitlyn Comstock3, Avinaash K. Sandhu3, Aakanksha R. Kapoor1,2, Yinan Hui5, Samuel K. Ayeh1,2, Rokeya Tasneen1,2, Stefanie Krug1,2, Carina Danchik1,2, Tianyin Wang3, Courtney Schill3, Richard B. Markham3* and Petros C. Karakousis1,2*

1Division of Infectious Diseases, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, United States, 2Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States, 3W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States, 4Division of Hematological Malignancies, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University Hospital, Baltimore, MD, United States

Lengthy tuberculosis (TB) treatment is required to overcome the ability of a subpopulation of persistent Mycobacterium tuberculosis (Mtb) to remain in a non-replicating, antibiotic-tolerant state characterized by metabolic remodeling, including induction of the RelMtb-mediated stringent response. We developed a novel therapeutic DNA vaccine containing a fusion of the relMtb gene with the gene encoding the immature dendritic cell-targeting chemokine, MIP-3α/CCL20. To augment mucosal immune responses, intranasal delivery was also evaluated. We found that intramuscular delivery of the MIP-3α/relMtb (fusion) vaccine or intranasal delivery of the relMtb (non-fusion) vaccine potentiate isoniazid activity more than intramuscular delivery of the DNA vaccine expressing relMtb alone in a chronic TB mouse model (absolute reduction of Mtb burden: 0.63 log10 and 0.5 log10 colony-forming units, respectively; P=0.0002 and P=0.0052), inducing pronounced Mtb-protective immune signatures. The combined approach involving intranasal delivery of the DNA MIP-3α/relMtb fusion vaccine demonstrated the greatest mycobactericidal activity together with isoniazid when compared to each approach alone (absolute reduction of Mtb burden: 1.13 log10, when compared to the intramuscular vaccine targeting relMtb alone; P<0.0001), as well as robust systemic and local Th1 and Th17 responses. This DNA vaccination strategy may be a promising adjunctive approach combined with standard
therapy to shorten curative TB treatment, and also serves as proof of concept for treating other chronic bacterial infections.

KEYWORDS
Mycobacterium tuberculosis, tuberculosis DNA vaccines, persistence, stringent response, immunotherapy, intranasal route, T cells

Introduction

Tuberculosis (TB) is a major cause of morbidity, and the second leading infectious killer after COVID-19 worldwide (1). The current six-month regimen, consisting of isoniazid (INH), rifampin, pyrazinamide and ethambutol, has high efficacy against drug-sensitive TB, but its length and complexity contributes to treatment interruptions that jeopardize cure and promote drug resistance (2, 3). Although novel, treatment-shortening antibiotic regimens have shown promising results in international clinical trials (4, 5), the resources required for direct observation of daily treatment and the associated costs may still pose barriers to their implementation in TB-endemic countries. Recent work has focused on adjunctive, host-directed strategies to simplify and shorten the course of TB therapy (6).

The need for prolonged TB treatment is believed to reflect the unique ability of a subpopulation of Mycobacterium tuberculosis (Mtb) bacilli within the infected host to remain in a nonreplicating, persistent state (7) characterized by tolerance to first-line anti-TB drugs, like INH, which more effectively targets actively dividing bacilli (8–11). One of the key bacterial pathways implicated in antibiotic tolerance is the stringent response, which is regulated by the (p)ppGpp synthase/hydrolase, Rv2583c (RelMtb) (12, 13). RelMtb deficiency results in defective Mtb survival under nutrient starvation (14) and in mouse lungs (15) and mouse hypoxic granulomas (16), reduced virulence in guinea pigs (17) and C3HeB/FeJ mice (18), and increased Mtb susceptibility to INH in mouse lungs (18), rendering RelMtb an attractive target for novel antitubercular therapies, including for drug-resistant TB (13).

We previously showed that intramuscular (IM) delivery of a DNA vaccine expressing relMtb enhanced the mycobactericidal activity of INH in a murine TB model (3, 19). In independent studies, our group has shown the enhanced efficacy of vaccines when the antigen of interest is fused to the gene encoding the chemokine Macrophage Inflammatory Protein-3 alpha/C-C Motif Chemokine Ligand 20 (MIP-3α/CCL20) (20–22). These earlier studies have also demonstrated that no host immune response is elicited to the autologous chemokine component of the vaccine (20–22). Since T-cell immunity is required to control Mtb infection (6), we hypothesized that fusion of relMtb to the chemokine gene MIP-3α (yielding MIP-3α/relMtb or “fusion vaccine”) would enhance the immunogenicity of the relMtb vaccine and further potentiate the mycobactericidal activity of INH in vivo.

Protection against pulmonary TB is associated with the ability of anti-Mtb T cells to exit the pulmonary vasculature and enter into the lung parenchyma and airways (23). Intranasal (IN) vaccination has been shown to promote recruitment of antigen-experienced T cells to these restricted lung compartments in contrast to parenteral immunization (23). Thus, we also hypothesized that IN administration of the vaccine expressing relMtb alone or the fusion vaccine would further augment T-cell responses within the lung, the primary site of Mtb infection.

Here, we present our bacteriological and immunological findings of a DNA vaccine expressing relMtb alone or the fusion construct, administered by the IM or IN route, in a murine model of chronic TB. Our results indicate that IM delivery of the MIP-3α/relMtb fusion vaccine or IN delivery of the relMtb vaccine yielded statistically equivalent improvement of mycobacterial outcomes compared to IM delivery of the relMtb vaccine. IN delivery of the MIP-3α/relMtb fusion vaccine (“optimized vaccination strategy”) yielded the highest additive therapeutic effect compared to each single novel approach alone.

Methods

Bacteria and growth conditions

Wild-type Mtb H37Rv was grown in Middlebrook 7H9 broth (Difco, Sparks, MD) supplemented with 10% oleic acid-albumin-dextrose- catalase (OADC, Difco), 0.2% glycerol, and 0.05% Tween-80 at 37°C in a roller bottle (3).
Antigen preparation

The previously generated relMtb expression plasmid, pET15b [relMtb] (3, 19), was used for expression and purification of recombinant RelMtb protein. Escherichia coli BL21 (DE3) RP competent cells (Stratagene) were transformed with pET15b[relMtb]. Transformed bacteria were selected with ampicillin (100 mg/ml), and cloning was confirmed by DNA sequencing. Protein expression was performed using standard protocols and purification was performed using Ni-NTA Agarose (Qiagen). Recombinant RelMtb protein (87 kDa) was purified from the cell lysate using a Ni-NTA resin column. The purity was confirmed by SDS-PAGE gel and immunoblot analyses. The protein concentration was determined using a BCA protein assay with BSA as the standard (Thermo Fisher). Recombinant RelMtb has been shown previously to retain (p) ppGpp synthesis and hydrolysis activities and can serve as an antigen to measure RelMtb-specific T-cell responses ex vivo (3, 19).

DNA vaccines

The plasmid pSectag2B encoding the full-length relMtb gene was used as the relMtb DNA vaccine (19). The relMtb gene was codon-optimized (Genscript) and fused to the mouse MIP-3α gene. The fusion product was cloned into pSectag2B, serving as the MIP-3α/relMtb, or “fusion” vaccine (Figure 1A, detailed sequence in Supplementary Appendix). Proper insertion was confirmed by sequencing and the expression of target genes was confirmed by transfection of 293T cells in lysates and supernatants. Vaccination plasmids were selected by ampicillin (100 μg/ml) and extracted from E. coli DH5-α (Invitrogen™ ThermoFisher Scientific, Waltham, MA) using Qiagen® (Germantown, MD) EndoFree® Plasmid Kits and were diluted with endotoxin-free 1xPBS.

Mtb challenge study in mice

Seven to ten male and female C57BL/6 mice (8-10-week-old, The Jackson Laboratory) were aerosol-infected with ~100 bacilli of wild-type Mtb H37Rv using a Glas-Col Inhalation Exposure System (Terre Haute, IN). After 28 days of infection, the mice received INH in a concentration of 10 mg/kg dissolved in total volume of 100 μl of distilled water per mouse. INH was administered by esophageal gavage once daily (5 days/week) and mice were randomized to receive the relMtb vaccine or the fusion vaccine by the IM or IN route. The mice were vaccinated three times at one-week intervals. IM or IN delivery of each plasmid followed adequate anesthesia of mice by vaporized isoflurane. For IM vaccinations, each plasmid was injected bilaterally into the quadriceps femoris muscle of the mice (50 μL in each quadriceps), followed by local electroporation using...
an ECM830 square wave electroporation (EP) system (BTX Harvard Apparatus Company, Holliston, MA, USA), since EP can increase the antigen uptake up to 1000 times (24). Each of the two-needle array electrodes delivered 15 pulses of 72V (a 20-ms pulse duration at 200-ms intervals) (19). For IN vaccinations, each plasmid was administered into both nostrils (50 µL in each nostril) and mice were monitored in the upright position until complete recovery and vaccine absorption were assured. To compensate for the anticipated reduced plasmid uptake without EP, which cannot be used with the IN vaccination route, we increased the dose of the vaccine 10-fold. The mice were sacrificed 6 weeks and 10 weeks after treatment initiation. The spleens and left lungs were harvested and processed into single-cell suspensions. The cells were then filtered through a 70-mm nylon filter mesh to remove undigested tissue fragments and washed with complete RPMI medium. The right lungs were homogenized using glass homogenizers. Serial tenfold dilutions of lung homogenates in PBS were plated on 7H11 selective agar (BD) at the indicated time points. Plates were incubated at 37°C and colony-forming units (CFU) were counted 4 weeks later by at least 2 investigators (3, 19). All procedures were performed according to protocols approved by the Johns Hopkins University Institutional Animal Care and Use Committee.

Immunogenicity studies in mice

Three to five male and female C57BL/6 mice (8-10-week-old, Charles River Laboratory) were randomized to receive the relMtb or the fusion DNA vaccine by the IM or IN route. The mice were sacrificed 6 weeks after the primary vaccination. Spleens, draining lymph nodes (LNs), lungs and peripheral blood mononuclear cells (PBMCs) were collected and processed into single-cell suspensions individually.

Intracellular cytokine staining, flow cytometry analysis and fluorospot

Single-cell suspensions from spleens, draining LNs, lungs and PBMCs were prepared. Each tissue was stimulated individually with purified recombinant RelMtb protein at 37°C (3, 19) for various time intervals, from 12 hrs (IFN-γ, IL-17α, IL-2) to 24 hrs (TNF-α), depending on the cytokine of interest. For Intracellular Cytokine Staining (ICS), GolgiPlug cocktail (BD Pharmingen, San Diego, CA) was added for an additional 4 hours after stimulation (total, 16 and 28 hours, respectively) and cells were collected using FACS buffer (PBS + 0.5% Bovine serum albumin (Sigma-Aldrich, St. Louis, MO), stained with Zombie NIR™ Fixable Viability Kit (Biolegend Cat. No.: 423105) for 30 min, and washed with PBS buffer. Surface proteins were stained for 20 min, the cells were fixed and permeabilized with buffers from Biolegend intracellular fixation/permeabilization set following manufacturer protocols (Cat. No. 421002), intracellular proteins were stained for 20 min, and samples were washed and resuspended with FACS buffer. The following anti-mouse mAbs were used for ICS: PercPCy5.5 conjugated anti-CD3 (Biolegend Cat. No 100217), FITC-conjugated anti-CD4 (Biolegend Cat. No 100405), Alexa700 conjugated anti-CD8 (Biolegend Cat. No. 155022), PEcy7 conjugated anti-TNF-α, (Biolegend Cat. No. 506323), APC conjugated anti-IFN-γ (Biolegend Cat. No. 505809), BV421 conjugated anti-IL-2, (Biolegend Cat No 503825), PE conjugated anti-IL-17α (Biolegend Cat. No 506903). The Attune™ NXY (Thermo Fisher Scientific, Waltham, MA), and a BD™ LSRII flow cytometer was used. Flow data were analyzed by FlowJo Software (FlowJo 10.8.1, LLC Ashland, OR). Flow analysis included alive, gated, total T lymphocytes, including CD4+ and CD8+ T-cell subpopulations. For simplicity, the CD8+ subpopulation analysis is not reported if no substantial population to allow comparisons was detected (e.g., IL-17α). For FluoroSpot assays (Supplementary Data), kits with pre-coated plates for enumeration of cells secreting IFN-γ and IL-17A were purchased from Mabtech (Cat. No. FSP-414443-2). Spots were enumerated on an AID iSpot EliSpot/FluoroSpot Reader.

Statistics

Pairwise comparisons of group mean values for log_{10} CFU (microbiology data) and flow cytometry data were made using one-way analysis of variance followed by Tukey’s multiple comparisons test. Prism 9.3 (GraphPad Software, Inc. San Diego, CA) was utilized for statistical analyses and figure generation. To illustrate the aggregate cytokine data per group (Figure 4), fraction of total analysis was used and is displayed in stacked bars. In Figure 6, cytokine data were normalized (the total sum of all the experimental groups= 100%, total absolute number of alive cells=30,000). All error bars represent the estimation of the standard error of the mean, and all midlines represent the group mean. A significance level of α ≤ 0.05 was set for all experiments.

Results

Intramuscular administration of MIP-3α/relMtb fusion vaccine increases the mycobactericidal activity of INH and elicits robust systemic Th1 responses in a murine model of chronic TB

Four weeks after Mtb aerosol infection, C57BL/6 mice were treated daily with human-equivalent doses of oral INH for 10 weeks (Figure 1B). The MIP-3α/relMtb fusion vaccine [Figure 1A, detailed sequences are available in the Supplementary Appendix] was administered via the IM route weekly for 3 weeks. The original vaccination strategy (IM delivery of the
relMtb vaccine), which previously demonstrated therapeutic adjunctive activity together with INH (3, 19), served as our baseline comparator in this study (“comparator” vaccine). One negative control group received no treatment, while another group received INH only. All vaccinated groups received INH in addition to the tested vaccines. Since DNA vaccination alone did not exhibit significant mycobactericidal activity in prior work (19), this group was not included in the present study. At 10 weeks after primary vaccination via the IM route, greater reduction in the lung mycobacterial burden was observed in the group receiving the fusion vaccine along with INH compared to that receiving the comparator vaccine with INH [absolute reduction of mycobacterial burden: 0.63 log_{10} CFU (P=0.0001), Figure 1C]. Relative to the relMtb vaccine, the MIP-3α/relMtb fusion vaccine elicited substantially higher numbers of RelMtb-specific, IFN-γ-producing CD4+ and CD8+ T cells (P<0.0001 and P<0.0001, respectively; Figures 2A, B), TNF-α-producing CD4+ T cells (P=0.0076, Figure 2C), and IL-2-producing CD4+ and CD8+ T cells (P=0.005 and P=0.0001, respectively; Figures 2E, F) in the spleens of Mtb-infected mice, indicating that the fusion vaccine elicits more robust systemic Th1 responses compared to the comparator vaccine.

In an independent immunogenicity study using uninfected animals (Supplementary Figure 2), we also tested IFN-γ secretion in mouse spleens using Fluorospot (Supplementary Figures 2B, C). We found significantly higher secretion of RelMtb-specific IFN-γ in the spleens of mice receiving IM delivery of the IM fusion vaccine relative to those receiving IM delivery of the comparator vaccine (P=0.036). We also tested the T-cell responses in additional murine tissues, including PBMCs, across the experiment. The percentage of TNF-α-producing CD4+ T cells in the PBMC population starting at day 28 (P=0.036) and peaking at day 42 (P=0.018) after primary vaccination was significantly higher in the group receiving IM vaccination with the fusion vaccine vs. that receiving IM vaccination with the comparator vaccine (Supplementary Figure 2D).

In summary, IM delivery of the fusion vaccine demonstrated enhanced adjunctive mycobactericidal activity compared to IM delivery of the comparator vaccine and the former vaccination strategy was associated with increased systemic Th1 cytokines.

Intranasal delivery of the MIP-3α/relMtb fusion vaccine showed the greatest mycobactericidal activity in combination with INH, eliciting both robust local and systemic Th1/Th17 responses in a murine model of chronic TB.

Next, we investigated to what extent the IN route of vaccination could further enhance the adjunctive therapeutic activity of each vaccine compared to IM delivery. IN vaccination with the relMtb vaccine significantly enhanced the mycobactericidal activity of INH compared to IM vaccination with the same vaccine (“comparator vaccination strategy”)...
(absolute reduction of mycobacterial burden: 0.52 log_{10} CFU (P=0.0052); Figure 3). IN vaccination with the MIP-3α/relMtb fusion vaccine (hereafter referred to as the "optimized vaccination strategy") showed the greatest additive therapeutic effect in combination with INH relative to any other experimental group (Figure 3). The optimized vaccination strategy resulted in an absolute reduction in lung bacillary load of 1.81 log_{10} relative to the INH group, 1.13 log_{10} relative to the comparator vaccination strategy (P<0.0001); 0.5 log_{10} relative to IM delivery of the MIP-3α/relMtb fusion vaccine (P=0.0058; Figure 3); and 0.61 log_{10} relative to IN delivery of the relMtb vaccine (P<0.0001; Figure 3). At 10 weeks post-primary vaccination, the optimized vaccination strategy resulted in the greatest reduction in normalized mean lung weight, which serves as a proxy for total lung inflammation, relative to the INH only group (relative reduction in normalized lung weight= 42.4%; P<0.0002) and untreated control group (relative reduction in normalized lung weight= 66.3%; P<0.0001) (Supplementary Figure 1A). All the individual comparisons among the different experimental groups with respect to study endpoints are listed in Supplementary Table 1. Mean lung mycobacterial burdens at implantation (-4 weeks), initiation of treatment (0 weeks), and at 6 weeks and 10 weeks after the initiation of treatment for each experimental group are shown in Supplementary Figure 1B. Gross pathology photographs of representative lungs per experimental group are available in Supplementary Figure 1C.

Having established that IM vaccination with the MIP-3α/relMtb fusion vaccine induces enhanced systemic Th1 responses relative to the comparator vaccine (Figure 2), we next sought to investigate the effect of IN delivery of each vaccine on immune responses in the lungs, i.e., at the point of entry of Mtb. The optimized vaccination strategy group induced substantially greater numbers of RelMtb-specific, IFN-γ-producing CD4+ and CD8+ T cells (P=0.003 and P<0.0001, respectively; Figures 4A, B) and IL-17A-producing CD4+ T cells (P<0.0001; Figure 4C) in the lungs of Mtb-infected mice compared to IM delivery of the fusion vaccine.

In the context of superior local production of Th-1 and Th-17 pathway-related cytokines induced by the optimized vaccination strategy, we proceeded to compare the effect of IN delivery of the fusion vaccine on systemic Mtb-protective Th1 responses relative to IM administration of the same vaccine. We found that the IN delivery of the fusion vaccine (optimized vaccination strategy) elicits similarly high levels of RelMtb-specific, IFN-γ-producing CD4+ and CD8+ T cells (Figures 5A, B) and IL-2-producing CD4+ and CD8+ T cells (Figures 5C, D) in Mtb-infected spleens compared to the IM delivery of
the same vaccine. Of interest, the percentage of RelMtb-specific, TNF-α-producing CD4+ and CD8+ T cells derived from spleens was significantly higher following IN vs. IM delivery of the fusion vaccine (P<0.0001 and P<0.0001, respectively; Figures 5E, F). Furthermore, the number of IL-17A-producing CD4+ T cells in the spleens of mice receiving IN vaccination with the fusion vaccine was also significantly higher compared to those of mice receiving the IM vaccination with the same vaccine (P<0.0001; Figure 5G).

In an independent immunogenicity study using uninfected animals (Supplementary Figure 2A), we also tested the RelMtb-specific, IL-17A secretion in mouse spleens using Fluorospot (Supplementary Figures 3A, B). We confirmed the significantly higher production of the RelMtb-specific IL-17A in the tissues of mice vaccinated with the optimized vaccination strategy compared to those receiving the fusion vaccine via the IM route (P=0.0079). The percentage of RelMtb-specific, IL-17A-producing CD4+ T cells in the PBMCs was significantly higher in the optimized vaccination strategy group vs. the IM fusion vaccine group (Supplementary Figure 3C). We also tested the T-cell responses in additional murine tissues, including draining LNs (inguinal vs. mediastinal). The percentage of RelMtb-specific, IL-17A-producing CD4+ T cells in the LNs of mice vaccinated with the optimized vaccination strategy was significantly higher compared to those vaccinated with the fusion vaccine via the IM route (Supplementary Figure 3D).

Taken together, the optimized vaccination strategy, which was shown to have the most favorable microbiological outcomes relative to any other tested vaccination approach (Figure 3), was also found, in parallel, to be associated with significantly increased production of multiple cytokines associated with Mtb control, both systemically and locally in the lungs, i.e., at the site of infection (Figures 4 and 5). More specifically, compared to any other approach, the aggregate percentage of RelMtb-specific CD4+ and CD8+ T cells producing IL-17A, TNF-α, IFN-γ, or IL-2 in the spleens and lungs of Mtb-infected animals was significantly greater in the recipients of the intranasally administered fusion vaccine (Figures 6A–C, Supplementary Table 2).

### Discussion

The development of novel immunotherapeutic regimens that synergize with antibiotics to accelerate curative TB treatment is an attractive strategy for improving medical adherence and treatment completion rates, and for reducing costs (25). In the current study, we show that MIP-3α fusion and the IN route of delivery individually enhance the therapeutic adjunctive activity of a DNA vaccine targeting an Mtb persistence antigen in a murine model of chronic TB. Importantly, the combined, optimized approach, i.e., IN immunization with a DNA fusion vaccine expressing MIP-3α/relMtb, was accompanied by additive Th1/Th17 responses, both systemically and at the site of infection. This novel optimized vaccination strategy may be a promising adjunctive therapeutic approach in combination with standard anti-TB therapy.

Although a functional immunological signature predictive of adequate TB control is still lacking, it is clear that CD4+ and CD8+ T cells are critical in developing immunity against Mtb (26–30). T-cell immunity to TB is likely mediated by a variety of T cells, especially those mediating Th1 and Th1/Th17-like responses (31). Chronic antigenic stimulation drives antigen-specific CD4+ T-cell functional exhaustion during murine Mtb infection (32), with important implications for TB vaccine design. Thus, subdominant Mtb antigens during chronic Mtb
infection, including RelMtb, which is induced during antitubercular treatment (3), may represent promising targets for therapeutic vaccines in an effort to “re-educate” the immune system to tailor host anti-TB responses. Notably, our group has also studied a therapeutic vaccine targeting ESAT-6, another key Mtb antigen, in two chronic TB animal models. We found that the vaccination group receiving the relMtb DNA vaccine and INH showed a significant reduction in mycobacterial burden in the lungs of C57BL/6 mice and guinea pigs compared to the groups receiving esat6 DNA vaccine and INH, which did not differ from the control group (3). In the current study, we chose to focus on optimizing the efficacy of the relMtb DNA vaccine by boosting RelMtb-specific T-cell responses through enhanced engagement with immature DCs.

Immature DCs are critical for the activation of adaptive immunity, and, eventually, mature DCs trigger antigen-specific
naive T cells (33). Of note, only a small minority of DCs are attracted to sites of immunization (33), and, in the case of HIV and TB infections, a proportion of the attracted DCs may be dysfunctional (34). Fusion of the antigen of interest to the chemokine MIP-3α (or CCL20) targets the antigen to immature DCs (35). It has been shown that following naked DNA vaccination, epidermal cells secrete the antigen of interest-MIP-3α fusion construct (20, 36). The secreted fusion construct is taken up and internalized by skin Langerhans cells via the receptor for this chemokine, which is termed C-C Motif Chemokine Receptor 6 (CCR6) (36). The complex is then processed and presented in draining LNs to elicit efficient cellular and humoral responses (36). Enhanced efficacy has been shown compared to antigen-only vaccines in various systems (20–22). In a mouse melanoma model, our group has demonstrated that IM immunization with a DNA vaccine containing a fusion of MIP-3α with the tumor antigen gene gp100/Trp2 elicited greater numbers of tumor antigen-specific T cells and offered greater therapeutic benefit compared to the cognate vaccine lacking the MIP-3α fusion (20, 36). Importantly, MIP-3α has also been shown to play a key role in driving DC recruitment to the nasal mucosa (37). Indeed, we found that IM vaccination with the MIP-3α fusion construct corresponded to increased antigen-specific systemic Th1 responses (IFN-γ, TNF-α, IL-2 in the spleens and TFN-α in PBMCs), relative to the relMtb alone construct. Interestingly, although this vaccination strategy, i.e., IM vaccination with the MIP-3α/relMtb fusion construct, yielded improved microbiological outcomes when combined with INH compared to the non-fused relMtb vaccine, no Th1 response was observed in the lungs, the primary site of the infection.

Compelling evidence suggests that protection against respiratory pathogens, such as Mtb, is dependent on the presence of pathogen-specific immune cells at the primary site of infection (25, 38, 39). Pre-clinical studies have shown that parenteral immunization with TB vaccines can drive robust antigen-specific T-cell responses in the periphery, but these cells are unable to rapidly enter the restricted lung mucosal compartments and largely fail to restrict Mtb replication (40). In contrast, respiratory mucosal immunization generates a long-lasting population of tissue-resident T cells expressing homing molecules to allow preferential migration and residence in the airway lumen and lung parenchyma (39–41). These immune cells generate an important line of defense by establishing pathogen-specific immunity at the site of entry, providing markedly enhanced control against pulmonary Mtb infection (39–41). Importantly, after IN vaccination, these antigen-experienced, lung-resident, T-cells have been shown to produce IL-17A in addition to IFN-γ, expanding the known signature panel that may confer enhanced TB immunity (42–45). In the current study, we have shown for the first time that IN delivery of a vaccine expressing relMtb enhances the bactericidal activity of an antitubercular drug (INH) relative to IM delivery of the same vaccine. Importantly, the optimized approach of MIP-3α fusion and the IN route of immunization yielded the greatest additive adjunctive mycobactericidal activity with INH in murine lungs, resulting in an approximate 100-fold reduction in lung bacterial burden compared to INH alone. The optimized approach was associated with more robust Th1 (IFN-γ, TNF-α, IL-2) and Th17 responses (IL-17A) systemically (spleens and PBMCs), but also in the lungs and draining LNs (IFN-γ and IL-17A), the primary site of infection.

There are limitations in our study. Although our cytokine analysis allows us to make some initial associations between each vaccination strategy and T-cell responses, future studies are needed to elucidate in detail the mechanism of the tested therapeutic vaccines, including the contribution of B cells. Also, additional studies are needed to test the therapeutic efficacy of these vaccines in other animal models which more closely represent human TB pathology, such as guinea pigs and non human primates (46).

In conclusion, we have shown that IN immunization with a DNA vaccine expressing MIP-3α/relMtb generates strong, additive Th1 and Th17 responses and significantly potentiates the mycobactericidal activity of the first-line drug, INH. Further studies are required to elucidate the relative importance of the different effector mechanisms elicited by this immunization strategy and to refine our understanding of the host-pathogen interactions that result in the improved therapeutic effects. Other formulations of this vaccine construct, including RNA platform, will be also the subject of future studies. Ultimately, the potential utility of this vaccination combination strategy must be evaluated as an adjunctive therapeutic intervention in shortening the duration of curative treatment for active TB in relevant preclinical models.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

Ethics statement

The animal study was reviewed and approved by Johns Hopkins University Institutional Animal Care and Use Committee.

Author contributions

SKa, RBM and PCK conceived and designed the study and wrote the manuscript. JTG, AK and SKa performed the fusion
vaccine construction. SKa performed transfection of 293T cells and ran western blots in lysates and supernatants. SKa and KC performed RelMt protein expression, purification and verification. SKa performed growth, selection and extraction of vaccination plasmids. SKa and TK performed the in vivo vaccinations (immunogenicity and challenge study). SKa, PN, and TK administered daily INH treatments to mice (challenge study). SKa performed survival mouse tail bleeds weekly and isolated PBMCs for further analysis (immunogenity study). SKa, PN, TK, JTG, JRC, DQ, KC, AS, YH, SKr, and CD performed animal harvesting and subsequent animal tissue processing (immunogenicity and challenge study). PN, SKr, RT, and SC contributed to the in vivo challenge study design. SKa, TK and PN plated the homogenates of the infected lungs and performed colony-forming units counting and analysis. SKa and TK performed flow cytometry analysis and Fluoroscope. SKa, TK, and TW performed data and statistical analysis. SKa, JTG, PN, TK, JRC, DQ, KC, AS, AK, YH, SKr, RT, SC, CD, TW, CS, RBM and PCK interpreted the data and edited the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by NIH grants: R21AI140860 and R01AI148710 to RM and PK, T32 AI007291 and Potts Memorial Foundation Award to SK. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Acknowledgements

Content of this publication has been available online in BioRxiv preprint server (47). Illustrations were created with BioRender.com.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.972266/full#supplementary-material

References

1. WHO. Tuberculosis (2021). Available at: https://www.who.int/news-room/fact-sheets/detail/tuberculosis.

2. Fauci AS. Multidrug-resistant and extensively drug-resistant tuberculosis: the national institute of allergy and infectious diseases research agenda and recommendations for priority research. J Infect Dis (2008) 197(11):1493–8. doi: 10.1086/587904

3. Chuang YM, Dutta NK, Gordy JT, Campodónico VL, Pinn ML, Markham RB, et al. Antibiotic treatment shapes the antigenic environment during chronic TB infection, offering novel targets for therapeutic vaccination. Front Immunol (2020) 11:680. doi: 10.3389/fimmu.2020.00680

4. Nunn AJ, Phillips PP, Mitchison DA. Timing of relapse in short-course chemotherapy trials for tuberculosis. Int J Tuberc Lung Dis (2010) 14(2):241–2.

5. Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. New Engl J Med (2021) 384(18):1705–18. doi: 10.1056/NEJMoa2033400

6. Frank DJ, Horne DJ, Dutta NK, Shaku MT, Madenin R, Hawn TR, et al. Remembering the host in tuberculosis drug development. J Infect Dis (2019) 219(10):1518–24. doi: 10.1093/infdis/jiy712

7. McDermott W. Microbial persistence. Yale J Biol Med (1958) 30(4):257–91.

8. McDermott W. Inapparent infection: relation of latent and dormant infections to microbial persistence. Public Health Rep (1959) 74(6):485–99. doi: 10.2307/1990490

9. Winder FG, Collins PB. Inhibition by isoniazid of synthesis of mycolic acids in mycobacterium tuberculosis. J Gen Microbiol (1970) 63(1):41–8. doi: 10.1099/00221287-63-1-41

10. Takayama K, Wang L, David HL. Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of mycobacterium tuberculosis. Antimicrob Agents Chemother (1972) 2(1):29–35. doi: 10.1128/AAC.2.1.29

11. Tomasz A, Albino A, Zanati E. Multiple antibiotic resistance in a bacterium with suppressed autolytic system. Nature (1970) 227(5254):138–40. doi: 10.1038/227138a0

12. Prusa J, Zhu DX, Stallings CL. The stringent response and mycobacterium tuberculosis pathogenesis. Pathog Dis (2018) 76(5):fy6054. doi: 10.1093/femsdp/fy6054

13. Danchik C, Wang S, Karakousis PC. Targeting the mycobacterium tuberculosis stringent response as a strategy for shortening tuberculosis treatment. Front Microbiol (2021) 12:744167. doi: 10.3389/fmicb.2021.744167

14. Primm TP, Andersen SJ, Mizrahi V, Avarbock D, Rubin H, Barry CE3rd. The stringent response of mycobacterium tuberculosis is required for long-term survival. J Bacteriol (2000) 182(17):4889–98. doi: 10.1128/JB.182.17.4889-4898.2000

15. Dahl JL, Kraus CN, Boshoff HJ, Donn B, Kofsky LF, Karpinski A, et al. The role of RelMt-mediated adaptation to stationary phase in long-term persistence of mycobacterium tuberculosis in mice. Proc Natl Acad Sci U.S.A. (2003) 100(17):10026–31. doi: 10.1073/pnas.1631248100

16. Karakousis PC, Yoshimatsu T, Lamichhane G, Woolwine SC, Nuerberger EL, Grosset J, et al. Dormancy phenotype displayed by extracellular mycobacterium tuberculosis within artificial granulomas in mice. J Exp Med (2004) 200(5):647–57. doi: 10.1084/jem.20040646
17. Klinkenberg LG, Lee JH, Bishai WR, Karakousis PC. The stringent response is required for full virulence of mycobacterium tuberculosis in guinea pigs. J Infect Dis (2010) 200(9):1397–404. doi: 10.1086/565624

18. Dutta NK, Klinkenberg LG. Inhibiting the stringent response block mycobacterium tuberculosis entry into quiescence and reduces persistance. Sci Adv (2019) 5(3):eaav2104. doi: 10.1126/sciadv.aav2104

19. Chuang YM, Dutta NK, Hung CF, Wu TC, Rubin H, Karakousis PC. Stringent response factors PPX1 and PPK2 play an important role in mycobacterium tuberculosis metabolism, biofilm formation, and sensitivity to isoniazid in vitro. Antimicrob Agents Chemother (2016) 60(11):6460–70. doi: 10.1128/AAC.01399-16

20. Gordy JT, Luo K, Kapoor A, Kim ES, Ayeh SK, Karakousis PC, et al. Treatment with an immature dendritic cell-targeting vaccine supplemented with IFN-γ and an inhibitor of DNA methylation markedly enhances survival in a murine melanoma model. Cancer Immunol Immunother (2020) 69(4):569–80. doi: 10.1007/s00262-019-02471-0

21. Gordy JT, Luo K, Zhang H, Biragyn A, Markham RB. Fusion of the dendritic cell-targeting chemokine MIP3α to melanoma antigen Gp100 in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model. J Immunother Cancer (2016) 4:96. doi: 10.1186/s40425-016-0189-y

22. Luo K, Gordy JT, Zavala F, Markham RB. A chemokine-fusion vaccine targeting immature dendritic cells elicits elevated antibody responses to malaria sporozoites in infant macaques. Sci Rep (2021) 11(1):1210. doi:10.1038/s41598-020-79427-3

23. Lai R, Afkami S, Haddadi S, Jeyanathan M, Xing Z. Mucosal immunity and novel tuberculosis vaccine strategies: route of immunisation determined T-cell homing to restricted lung mucosal compartments. Eur Respir Rev (2015) 24 (136):356–60. doi:10.1183/16000617.0002515

24. Todorova B, Adam L, Culina S, Boisgard R, Martinon F, Cosma A, et al. Electroporation as a vaccine delivery system and a natural adjuvant to intradermal administration of plasmid DNA in macaques. Sci Rep (2017) 7(1):4122. doi:10.1038/s41598-017-04547-2

25. Afkami S, Villela AD, D’Agostino MR, Jeyanathan M, Gillgrass A, Xing Z. Advancing immunotherapeutic vaccine strategies against pulmonary tuberculosis. Front Immunol (2020) 11:2269. doi: 10.3389/fimmu.2020.557809

26. Caruso AM, Serbina N, Klein E, Trimbold K, Bloom BR, Flynn JL. Mice deficient in CD4 T cells have only transiently diminished levels of IFN-γ, yet succumb to tuberculosis. J Immunol (1999) 162(9):5407–16.

27. Lawn SD, Myer L, Edwards D, Bekker LG, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in south Africa. Science (2001).

28. Caruso AM, Serbina N, Klein E, Trimbold K, Bloom BR, Flynn JL. Mice deficient in CD4 T cells have only transiently diminished levels of IFN-γ, yet succumb to tuberculosis. J Immunol (1999) 162(9):5407–16.

29. Biragyn A, Kwak LW. B-cell malignancies as a model for cancer vaccines: from prototype protein to next generation genetic chemokine fusions. Immunol Res (1999) 17(6):115–26. doi: 10.1111/j.1600-065X.1999.tb01333.x

30. Kondama S, Abe N, Hirano T, Suzuki M. A single nasal dose of CCL20 chemokine induces dendritic cell recruitment and enhances nonotypic haemophilus influenzae-specific immune responses in the nasal mucosa. Acta Otolaryngol (2011) 131(9):969–96. doi: 10.3109/00016489.2011.576429

31. Jeyanathan M, Heriaxon A, Xing Z. Airway luminal T cells: a newcomer on the stage of TB vaccination strategies. Trends Immunol (2010) 31(7):247–52. doi: 10.1016/j.it.2010.05.002

32. Wang J, Theron S, Stokes RW, Santosoosso M, Huygen K, Zganiacz A, et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol (2004) 173(10):6355–67. doi: 10.4049/jimmunol.173.10.6357

33. Jeyanathan M, Afkami S, Khera A, Mandar T, Damjancovic D, Yao Y, et al. CXCR3 signaling is required for restricted homing of parenteral tuberculosis vaccine-induced T cells to both the lung parenchyma and airway. J Immunol (2017) 199(7):2555–69. doi: 10.4049/jimmunol.1700382

34. Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol (2009) 27:393–422. doi:10.1146/annurev.immunol.021908.132703

35. Chauside CN, Mille KHG. Next-generation pertussis vaccines based on the induction of protective T cells in the respiratory tract. Vaccines (2020) 8(4):621. doi:10.3390/vaccines8040621

36. Van Dis E, Sogi KM, Rae CS, Sivick KE, Surih NH, Leong ML, et al. STING-activating adjuvants elicit a Th17 immune response and protect against mycobacterium tuberculosis infection. Cell Rep (2018) 23(5):1435–47. doi: 10.1016/j.celrep.2018.04.003

37. Gopal R, Monin L, Slicht S, Uche U, Blanchard E, Fallert Junceto BA, et al. Unexpected role for IL-17 in protective immunity against hypervirulent mycobacterium tuberculosis HN878 infection. Pathog Glob Health (2014) 10(5):e1004099. doi: 10.1177/0075587X14056530

38. Ghader SA, Pearl JE, Sakamoto K, Gilmarunt L, Bell GK, Jelley-Gibbs DM, et al. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-γ responses if IL-12p70 is available. J Immunol (2005) 175(2):788–95. doi: 10.4049/jimmunol.175.2.788

39. Gong W, Liang Y, Wu X. Animal models of tuberculosis vaccine research: An important component in the fight against tuberculosis. BioMed Res Int (2020) 2020:4263079. doi: 10.1155/2020/4263079

40. Karanika S, Gordy JT, Neupane P, Karanantos T, Ruelas Castillo J, Quijada D, et al. An intranasal stringent response vaccine targeting dendritic cells as a novel adjunctive therapy against tuberculosis. BioRxiv. (2022). doi: 10.1101/2022.04.19.488816

COPRİGHT © 2022 Karanika, Gordy, Neupane, Karanantos, Ruelas Castillo, Quijada, Cornstock, Sandhu, Kapoor, Hui, Ayeh, Tasneen, Krug, Danchik, Wang, Schill, Markham and Karakousis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.